SmartMetric (SMME) 10-Q 23 Nov 20 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2020	Nov. 19, 2020
Document Information Line Items
Entity Registrant Name	SmartMetric, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		406,727,465
Amendment Flag	false
Entity Central Index Key	0001301991
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-54853
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	No

Condensed Consolidated Balance

Condensed Consolidated Balance Sheet - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Current assets:
Cash	$ 27,500	$ 71,377
Deferred financing costs	35,000	35,000
Prepaid expenses and other current assets		7,017
Total current assets	62,500	113,394
Total assets	62,500	113,394
Current liabilities:
Accounts payable and accrued expenses	933,925	916,728
Liability for stock to be issued	127,409	50,000
Deferred Officer's salary	744,115	759,948
Related party interest payable	162,642	149,481
Dividends payable	3,691	2,945
Due to shareholders	41,343	41,343
PPP loan	20,832	20,832
Convertible note payable, net of discount	33,804	32,127
Derivative liability	42,767
Shareholder loan	1,709
Total current liabilities	2,112,237	1,973,404
Total liabilities	2,112,237	1,973,404
Commitments and contingencies (see note 4)
Series C mandatory redeemable convertible preferred stock, net of discount $29,585, authorized 1,000,000 shares 148,000 and 117,200 shares issued and outstanding, respectively	97,575	101,661
Stockholders’ deficit:
Series B Preferred stock, $.001 par value; 5,000,000 shares authorized, 610,000 and 610,000 shares issued and outstanding	610	610
Common stock, $.001 par value; 600,000,000 shares authorized, 385,555,260 and 379,523,000 shares issued and outstanding , respectively	385,556	379,524
Additional paid-in capital	25,463,520	25,429,259
Accumulated deficit	(27,996,998)	(27,771,064)
Total stockholders' deficit	(2,147,312)	(1,961,671)
Total liabilities and stockholders' deficit	$ 62,500	$ 113,394

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Parentheticals) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Net of discount (in Dollars)	$ 29,585
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, issued	385,555,260	379,523,000
Common stock, outstanding	385,555,260	379,523,000
Series C redeemable convertible preferred stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	148,000	117,200
Preferred stock, outstanding	148,000	117,200
Series B Preferred stock
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	610,000	610,000
Preferred stock, outstanding	610,000	610,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues
Expenses:
Officer's salary	47,500	47,500
Other general and administrative	124,596	132,859
Research and development	22,206	21,112
Total operating expenses	194,302	201,471
Loss from operations
Other income and expenses	(194,302)	(201,471)
Interest expense	(28,669)	(13,825)
Gain on change in fair value of derivatives	1,064
Net loss before income taxes	(221,907)	(215,296)
Income tax	0	0
Net loss	(221,907)	(215,296)
Series C Preferred stock dividends	(4,029)	(11,725)
Net loss available for common stockholders	$ (225,936)	$ (227,021)
Net loss per share, basic and diluted (in Dollars per share)	$ 0	$ 0
Weighted average number of common shares outstanding, basic and diluted (in Shares)	381,988,718	272,691,261

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' (Deficit) (Unaudited) - USD ($)	Preferred Series B Stock	Common Stock	Additional Paid In Capital	Accumulated Deficit	Total
Balance at Jun. 30, 2019	$ 610	$ 264,649	$ 24,663,528	$ (26,933,461)	$ (2,004,674)
Balance (in Shares) at Jun. 30, 2019	610,000	264,648,821
Shares issued of common stock and warrants for cash		$ 7,992	218,008		226,000
Shares issued of common stock and warrants for cash (in Shares)		7,991,662
Preferred C shares converted to common stock		$ 3,224	63,289		66,513
Preferred C shares converted to common stock (in Shares)		3,224,643
Preferred Shares C Dividends				(11,725)	(11,725)
Net loss for the period				(215,296)	(215,296)
Balance at Sep. 30, 2019	$ 610	$ 275,865	24,944,825	(27,160,482)	(1,939,182)
Balance (in Shares) at Sep. 30, 2019	610,000	275,865,126
Balance at Jun. 30, 2020	$ 610	$ 379,523	25,429,261	(27,771,062)	(1,961,671)
Balance (in Shares) at Jun. 30, 2020	610,000	379,523,000
Shares issued of common for services		$ 585	2,340		2,926
Shares issued of common for services (in Shares)		585,000
Preferred C shares converted to common stock		$ 5,447	31,921		37,369
Preferred C shares converted to common stock (in Shares)		5,447,260
Preferred Shares C Dividends				(4,029)	(4,029)
Net loss for the period				(221,907)	(221,907)
Balance at Sep. 30, 2020	$ 610	$ 385,555	$ 25,463,522	$ (27,996,998)	$ (2,147,312)
Balance (in Shares) at Sep. 30, 2020	610,000	385,555,260

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (221,907)	$ (215,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-Cash Financing Expense	13,831
Gain on change in fair value of derivative liability	(1,064)
Amortization of Debt Discount	1,677
Shares issued for services	2,926
Changes in assets and liabilities
Decrease (Increase) in prepaid expenses and other current assets	7,017	(7,567)
Increase in accounts payable and accrued expenses	17,196	10,082
Decrease in deferred officer salary	(15,833)
Increase in accrued interest payable	13,161	13,825
Net cash used in operating activities	(182,996)	(198,956)
CASH FLOWS FROM FINANCING ACTIVITIES
Loans from related parties	1,709	10,300
Proceeds from sale of common stock in shares payable	77,410	133,495
Proceeds from sale of Series C Preferred stock	60,000	45,000
Net cash provided by financing activities	139,119	188,795
NET DECREASE IN CASH	(43,877)	(10,161)
CASH BEGINNING OF PERIOD	71,377	10,161
END OF PERIOD	27,500	0
CASH PAID DURING THE PERIOD FOR:
Income taxes
Interest
Non cash investing and financing activity
Conversion of 41,800 Preferred C shares into 5,447,260 Shares of common stock	$ 37,369

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	3 Months Ended
	Sep. 30, 2020shares
Common Stock
Conversion of shares	5,447,260
Preferred C Shares
Conversion of shares	41,800

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	NOTE 1 ORGANIZATION AND BASIS OF PRESENTATION SmartMetric, Inc. (the “Company” or “SmartMetric”) was incorporated in the State of Nevada on December 18, 2002. SmartMetric’s main product is a fingerprint sensor-activated card with a finger sensor onboard the card and a built-in rechargeable battery for portable biometric identification. This card may be referred to as a biometric card or the SmartMetric Biometric Datacard. SmartMetric has completed development of its card along with pre-mass manufacturing cards but has not yet begun to mass manufacture the biometric fingerprint activated cards. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management of the Company, the accompanying unaudited financial statements contain all the adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the three months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021. For further information, refer to the financial statements and the footnotes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020, as filed with the Securities and Exchange Commission on October 20, 2020. The consolidated balance sheet as of June 30, 2020, has been derived from the audited financial statements at that date, but does not include all the information and footnotes required by US GAAP for complete financial statements. Going Concern As shown in the accompanying condensed consolidated financial statements the Company has sustained recurring losses of $225,936 and $227,021 for the three months ended September 30, 2020 and 2019, respectively, and has an accumulated deficit of $27,996,998 at September 30, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date of this filing. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The COVID-19 has had an impact on SmartMetric’s final card production. While the delays are due to supply line disruption, the Company is confident that these delays will be short-lived based on advice from our manufacturing partners, manufacturing alternatives and alternative supply lines that are being put into place by the Company. Management believes that the Company’s capital requirements will depend on many factors. These factors include product marketing and distribution. The management plans include equity sales and borrowing in order to fund the operations. The Company plans to continue its relationship with Geneva Roth Remark in order to raise capital through means other than private placement stock sales. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. On March 5, 2020, the Company entered into an agreement with GHS Investments, LLC whereas the investor agrees to invest up to four million dollar ($4,000,000) over the 36 months immediately subsequent to the effective date of the agreement. As of the date of this filing, the registration is not effective , and is pending review by the Securities and Exchange Commission. In December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China (“COVID-19”) and has since spread worldwide, including to the Unites States, posing public health risks that have reached pandemic proportions (the “COVID-19 Pandemic”). The COVID-19 Pandemic poses a threat to the health and economic wellbeing of our employees, customers and vendors. Like most businesses world-wide, the COVID-19 Pandemic has impacted the Company financially; delaying the beginning of production. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, SmartMetric Australia Pty. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for electronics design and engineering, software design and engineering, component sourcing, component engineering, manufacturing, product trials, compensation and consulting costs. Recent Accounting Pronouncements The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. Loss Per Share of Common Stock In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2020 and 2019, 82,882,681 and 29,403,406 dilutive shares were excluded from the calculation of diluted loss per common share, with all dilutive shares being Common stock warrants at September 30, 2020 and 2019, as their effect would be anti-dilutive. Stock-Based Compensation The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation Equity-Based Payments to Non-Employees Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

Prepaid Expenses

Prepaid Expenses	3 Months Ended
	Sep. 30, 2020
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 PREPAID EXPENSES Prepaid expenses represent the unexpired terms of various consulting agreements as well as advance rental payments. Prepaid expenses at September 30, 2020 were $0.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 - COMMITMENTS AND CONTINGENCIES Lease Agreement The Company’s main office is in Las Vegas, Nevada. Rent expense under all leases for the three months ended September 30, 2020 and 2019 was $766 and $1,166 respectively. The Company maintains only one office. This office is in Las Vegas, NV and is a month-to-month lease. Related Party Transactions The Company’s Chief Executive Officer has made cash advances to the Company with an aggregate amount due of $1,709 and $0 as of September 30, 2020 and June 30, 2020, respectively. These advances bear interest at 7.00% per annum. As of September 30, 2020 and June 30, 2020, the Company has accrued the amounts of $744,115 and $759,948, respectively, as deferred Officer’s salary for the difference between the president’s annual salary and the amounts paid. As a result of these shareholder loans and deferred officer salary, the Company has accrued a balance of $162,642 and $149,481 as interest payable as of September 30, 2020 and June 30, 2020. On September 11, 2017, we received a license to certain patents from Chaya Hendrick, our founder and CEO, related to our technologies until the expiration of the patents. As consideration, we issued Chaya Hendrick, or her assigns, (i) 200,000 shares of Series B Convertible Preferred Stock, (ii) a royalty equal to 5% of gross revenues derived from products sold related to the patents, and (iii) certain minimum required payments beginning at $50,000 and doubling each year thereafter. The Series B Preferred Shares may be converted at the election of holder on a basis for 50 common shares for each preferred share at any time or an aggregate of 10,000,000 common shares in exchange for all 200,000 preferred shares. Our CEO maintains an employment agreement that stipulates a $190,000 annual salary. This agreement is in effect until mutual agreement between its CEO and the Company to terminate. Litigation From time to time we may be a defendant or plaintiff in various legal proceedings arising in the normal course of our business. As of the date of this Quarterly Report, there are no material pending legal or governmental proceedings relating to us or properties to which we are a party, and, to our knowledge, there are no material proceedings to which any of our directors, executive officers or affiliates are a party adverse to us or which have a material interest adverse to us.

Debt

Debt	3 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
DEBT	NOTE 5 - DEBT On April 17, 2020, we received funds under the Paycheck Protection Program, a part of the CARES Act. The loan is serviced by Chase Bank, and the application for these funds required us to, in good faith, certify that the current economic uncertainty made the loan necessary to support our ongoing operations. We used the funds for payroll and related costs. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on our ability to adhere to the forgiveness criteria. The loan bears interest at a rate of 0.98% per annum and matures on April 6, 2022, with the first payment being deferred until October 6, 2020. Under the terms of the PPP, certain amounts may be forgiven if they are used in accordance with the CARES Act. The Company believes that the full amount of the $20,832 Paycheck Protection Program loan will be forgiven and therefore the entire loan is classified as current liability in the accompanying Balance Sheet. On March 5, 2020, the Company issued a $35,000 10% convertible note to the investor in relation to the equity financing agreement (Note 6). The note is due on December 5, 2020 and is convertible at a rate of $0.0175 per share which resulted in a discount from the beneficial conversion feature totaling $5,000. During the year ended June 30, 2020, $2,127 of the debt discount was amortized . For the three month period ended September 30, 2020, $3,804 of the debt discount was amortized. As of September 30, 2020, the note was shown net of unamortized discount of $33,804.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 6 STOCKHOLDERS’ DEFICIT Preferred Stock As of September 30, 2020, the Company has 5,000,000 shares of Class B preferred stock, par value $0.001, authorized and 610,000 shares issued and outstanding. On December 11, 2009, the Company filed a Certificate of Designation with the State of Nevada, to designate 500,000 shares of preferred stock as Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”). Effective November 5, 2014, the number of shares designated as Series B Convertible Preferred Stock was increased to 5,000,000 shares. Each share of Series B Convertible Preferred Stock has a par value of $0.001, and a stated value equal to $5.00 (“Stated Value”). Holders of the Series B Convertible Preferred Stock are entitled to receive dividends or other distributions with the holders of the common stock of the Company on an as converted basis when, as, and if declared by the directors of the Company. Holders of the Series B Convertible Preferred Stock are entitled to convert each share of the Series B Convertible Preferred Stock into fifty (50) shares of common stock. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, holders of the Series B Convertible Preferred Stock are entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value, pro rata with the holders of the common stock. The Company issued 200,000 Series B preferred shares upon its inception in 2004. In October 2015, the Company issued 200,000 Series B preferred shares. On September 11, 2017, the Company issued an additional 210,000 shares of Series B preferred shares to its CEO, Chaya Hendrick, in consideration for grant of exclusive rights to the licensed patent. Class A Common Stock During the three month period ending December 31, 2019, the Company increased its total number of shares of authorized capital stock to 600,000,000 shares, par value $0.001 per share. Common Stock As of September 30, 2020, the Company had 385,555,260 shares of common stock issued and outstanding. ● During the three months ended September 30, 2020, the Company sold 17,500,000 shares of common stock for net proceeds of $77,409. With these issuances the company also issued warrants to purchase: (i) 17,500,000 shares at prices ranging from $0.05 to $0.10 per share and (ii) 14,500,000 shares at prices ranging from $0.10 to $0.20. The warrants expire at various times through September 21, 2022. None of the 17,500,000 shares were issued during the quarter ended September 30, 2020, and were recognized as stock payable. ● During the three months ended September 30, 2020, the Company issued 6,032,260 shares. Of these shares, 585,000 were issued for consulting services and 5,447,260 were converted from Preferred shares. ● During the three months ended September 30, 2019, the Company sold for cash 6,337,500 shares of common stock and warrants to purchase: (i) 6,337,500 shares at prices ranging from $0.10 per share to $0.25 per share for net proceeds of $133,495. The warrants expire at various times through September 17, 2021. None of these shares were issued during the quarter ended September 30, 2019, with all 6,337,500 shares being recorded as stock payable. During the three months ended September 30, 2019, the Company issued 11,216,305 shares for cash. Of these shares, 7,991,662 were issued from stock payable and 3,224,643 were converted from Preferred shares. Equity Financing Agreement On March 5, 2020, the Company entered into an equity financing agreement with GHS Investments, LLC, a Nevada limited liability company (“Investor”). Pursuant to the agreement, the Company agrees the sell to the investor an indeterminate amount of shares of the Company’s common stock, par value $0.001 per share, up to an aggregate price of four million dollars ($4,000,000). Pursuant to the agreement, the Company is required, to within sixty (60) calendar days upon the date of execution of this agreement, use its best efforts to file with the SEC a registration statement or registration statements (as is necessary) on Form S-1, covering the resale of all of the registrable securities, which registration statement(s) shall state that, in accordance with Rule 416 promulgated under the 1933 Act, such registration statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon stock splits, stock dividends or similar transactions. Pursuant to this equity financing agreement, the Company filed the Registration S-1 on August 6, 2020. The Registration Statement is not effective as of the date of this filing, and is currently being reviewed by The Securities and Exchange Commission. Following effectiveness of the Registration Statement, the Company shall have the discretion to deliver puts to GHS and GHS will be obligated to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice shall not exceed two hundred percent (200%) of the average daily trading dollar volume of the Company’s Common Stock during the ten (10) trading days preceding the put, so long as such dollar amount does not exceed $500,000. Pursuant to the Equity Financing Agreement, GHS and its affiliates will not be permitted to purchase and the Company may not put shares of the Company’s Common Stock to GHS that would result in GHS’s beneficial ownership, equaling more than 4.99% of the Company’s outstanding Common Stock. The price of each put share shall be equal to eighty percent (80%) of the Market Price (as defined in the Equity Financing Agreement). Puts may be delivered by the Company to GHS until the earlier of thirty-six (36) months after the effectiveness of the Registration Statement. Concurrently with the execution of the equity financing agreement, the company entered into a convertible promissory note, for the principal balance of $35,000. Per the terms of the convertible note agreement, the Company agrees to pay the investor interest at the rate of ten percent (10%) until it is due on December 5, 2020. The holder shall have the right at any time to convert all or any part of the outstanding and unpaid principal and interest at a fixed conversion price of $0.0175. See Note 5. The $35,000 has been recognized as deferred financing costs in current assets on the accompanying Consolidated Balance Sheet, and will be charged against the gross proceeds of each put when received. Although the Company has not as of yet put to GHS, the agreement is in effect for three years, through March, 2023, and as the Company does plan to put to GHS, the Company has determined it is proper for the deferred costs to remain for the length of the agreement . Warrants From time to time the Company granted warrants in connection with private placements of securities, as described herein. As of September 30, 2020, and June 30, 2020, the following is a breakdown of the warrant activity: Range of Exercise Prices Number of Weighted-Average Weighted- Number Weighted- Warrants Outstanding and Exercisable at September 30, 2020: $0.05 - $1.00 82,882,681 1.27 $ 0.28 82,882,681 $ 0.28 Warrants Outstanding and Exercisable at June 30, 2020: $0.20 - $1.00 53,280,406 1.12 $ 0.34 53,280,406 $ 0.34 Warrant Activity: September 30, 2020: Outstanding - June 30, 2020 53,280,406 Issued 32,000,000 Exercised — Expired (2,397,725 ) Outstanding - September 30, 2020 82,882,681 September 30, 2019: Outstanding - June 30, 2019 26,526,234 Issued 6,337,500 Exercised — Expired (3,460,328 ) Outstanding - September 30, 2019 29,403,406 At September 30, 2020, all 82,882,681 warrants are vested and all 84,882,681 warrants expire at various times prior to September 21, 2022.

Mandatory Redeemable Convertibl

Mandatory Redeemable Convertible Preferred Stock	3 Months Ended
	Sep. 30, 2020
Mandatory Redeemable Convertible Preferred Stock [Abstract]
MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK	NOTE 7 MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK Issuances of Series C Mandatory Redeemable Convertible Preferred Stock On January 10, 2019, the Board of Directors of the Company adopted a resolution pursuant to the Company’s Certificate of Incorporation, as amended, providing for the designations, preferences and relative, participating, optional and other rights, and the qualifications, limitations and restrictions, of the Series C Convertible Preferred Stock. On January 14, 2019, the Company filed a Certificate of Designations for a Series C Convertible Preferred Stock. The authorized number of Series C Convertible Preferred Stock is 1,000,000 shares, par value 0.001. The Series C Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding-up or dissolution, rank: (a) senior with respect to dividends and right of The number of Series C, mandatory redeemable convertible preferred stock shares issued and outstanding were 148,000 and 117,200 , respectively, for September 30, 2020 and June 30, 2020. The Holder shall have the right at any time during the period beginning on the date which is six (6) months following the Issuance Date, to convert all or any part of the outstanding Series C Preferred Stock into fully paid and non-assessable shares of Common Stock at the Variable Conversion Price. The “Variable Conversion Price” shall mean 71% multiplied by the Market Price (representing a discount rate of 29%). “Market Price” means the average of the two (2) lowest Trading Prices (as defined here) for the Common Stock during the fifteen (15) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. The Preferred shares are convertible at 71% of the average market price of the Company’s stock based on the lowest two (2) market closes fifteen (15) days prior. The Company analyzed the conversion feature and determined it was required to be bifurcated and recognized as a derivative liability. The derivative at inception was valued at $43,945, based on the Black Scholes Merton pricing model. As the fair value of the derivative and the shares issued at inception were in excess of the face amount of the Preferred shares , the Company recorded a discount in the amount of $30,000 to be amortized utilizing the effective interest method of accretion over the term of the note. The assumptions used in the model were a conversion price of $0.0071, a stock volatility of between 225% and 242% and a discount rate of 0.15%, based on the current 18-month interest rates of the U.S. T-Bill. The following table provides a summary of the changes in fair value, including net transfers in and out of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the three months ended June 30, 2020. Balance, June 25, 2020: $ 43,831 Unamortized discount originated from derivative liabilities: 30,000 Financing costs recorded: 13,831 Derivative liability: (43,831 ) Change in fair market value of derivative liabilities: (1,064 ) Balance, June 30, 2020 $ 42,767 On the date which is eighteen (18) months following the Issuance Date or upon the occurrence of an Event of Default (the “Mandatory Redemption Date”), the Company shall redeem all of the shares of Series C Preferred Stock of the Holder (which have not been previously redeemed or converted). With five (5) days of the Mandatory Redemption Date, the Company shall make payment to each Holder of an amount in cash equal to the total number of shares of Series C Preferred Stock held by such Holder multiplied by the then current Stated Value. All shares of mandatorily redeemable convertible preferred stock have been presented outside of permanent equity in accordance with ASC 480, Classification and Measurement of Redeemable Securities The carrying value of the Series C mandatory redeemable convertible preferred stock at September 30, 2020 and 2019 was $97,575 and $90,751 net of discount, respectively. There were 72,600 Preferred C shares issued for net proceeds of $60,000 and 41,800 Preferred C shares converted to 5,447,260 Common shares for the three months ended September 30, 2020.

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year. Cumulative adjustments to the Company’s estimate are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company has estimated its effective tax rate to be 0%, based primarily on losses incurred and the uncertainty of realization of the tax benefit of such losses.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company has reviewed its operations subsequent to September 30, 2020 to the date these financial statements were issued. Between July 1, 2020 and November 17, 2020, the Company issued 21,117,205 shares of common stock. Of this amount, 6,172,205 shares were issued from 30,000 Preferred C shares that were converted and 14,945,000 shares were issued for cash and services.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for electronics design and engineering, software design and engineering, component sourcing, component engineering, manufacturing, product trials, compensation and consulting costs.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.
Loss Per Share of Common Stock	Loss Per Share of Common Stock In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2020 and 2019, 82,882,681 and 29,403,406 dilutive shares were excluded from the calculation of diluted loss per common share, with all dilutive shares being Common stock warrants at September 30, 2020 and 2019, as their effect would be anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation Equity-Based Payments to Non-Employees
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Schedule of share based compensation warrant activity	Range of Exercise Prices Number of Weighted-Average Weighted- Number Weighted- Warrants Outstanding and Exercisable at September 30, 2020: $0.05 - $1.00 82,882,681 1.27 $ 0.28 82,882,681 $ 0.28 Warrants Outstanding and Exercisable at June 30, 2020: $0.20 - $1.00 53,280,406 1.12 $ 0.34 53,280,406 $ 0.34
Schedule of warrant activity	Outstanding - June 30, 2020 53,280,406 Issued 32,000,000 Exercised — Expired (2,397,725 ) Outstanding - September 30, 2020 82,882,681 Outstanding - June 30, 2019 26,526,234 Issued 6,337,500 Exercised — Expired (3,460,328 ) Outstanding - September 30, 2019 29,403,406

Mandatory Redeemable Converti_2

Mandatory Redeemable Convertible Preferred Stock (Tables)	3 Months Ended
	Sep. 30, 2020
Mandatory Redeemable Convertible Preferred Stock [Abstract]
Schedule of derivative financial instruments, measured at fair value on a recurring basis	Balance, June 25, 2020: $ 43,831 Unamortized discount originated from derivative liabilities: 30,000 Financing costs recorded: 13,831 Derivative liability: (43,831 ) Change in fair market value of derivative liabilities: (1,064 ) Balance, June 30, 2020 $ 42,767

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details) - USD ($)	Mar. 05, 2020	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Organization and Basis of Presentation (Details) [Line Items]
Recurring losses		$ 225,936	$ 227,021
Accumulated deficit		$ (27,996,998)		$ (27,771,064)
GHS Investments, LLC [Member]
Organization and Basis of Presentation (Details) [Line Items]
Investor agrees to invest amount	$ (4,000,000)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Accounting Policies [Abstract]
Dilutive shares were excluded from diluted loss per common share	82,882,681	29,403,406

Prepaid Expenses (Details)

Prepaid Expenses (Details)	Sep. 30, 2020USD ($)
Prepaid Expenses [Abstract]
Prepaid expenses	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Sep. 11, 2017	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Commitments and Contingencies (Details) [Line Items]
Rent expense		$ 766	$ 1,166
Accrued the amounts		744,115		$ 759,948
Accrued balance of interest payable		162,642		149,481
Annual salary		190,000
Chief Executive Officer [Member]
Commitments and Contingencies (Details) [Line Items]
Aggregate amount due		$ 1,709		$ 0
Interest rate		7.00%
Related party transactions, description	(i) 200,000 shares of Series B Convertible Preferred Stock, (ii) a royalty equal to 5% of gross revenues derived from products sold related to the patents, and (iii) certain minimum required payments beginning at $50,000 and doubling each year thereafter. The Series B Preferred Shares may be converted at the election of holder on a basis for 50 common shares for each preferred share at any time or an aggregate of 10,000,000 common shares in exchange for all 200,000 preferred shares.

Debt (Details)

Debt (Details) - USD ($)	Mar. 05, 2020	Apr. 17, 2020	Sep. 30, 2020	Jun. 30, 2020
Debt (Details) [Line Items]
Loan bears interest, percentage		0.98%
Maturity date		Apr. 6, 2022
Loan amount		$ 20,832
Convertible note	$ 35,000		$ 33,804	$ 32,127
Convertible note, percentage	10.00%
Conversion price per share (in Dollars per share)			$ 0.0071
Beneficial conversion feature	$ 5,000
Amortization of debt discount			$ 1,677	$ 2,127
Amortization of debt discount			3,804
Unamortized discount net			$ 33,804
Debt [Member]
Debt (Details) [Line Items]
Conversion price per share (in Dollars per share)	$ 0.0175

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)	Mar. 05, 2020	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Sep. 11, 2017	Oct. 31, 2015	Nov. 05, 2014	Dec. 11, 2009
Stockholders' Deficit (Details) [Line Items]
Preferred stock, shares issued							200,000
Preferred stock shares increased					0.001
Shares issued		200,000
Capital stock, authorized					600,000,000
Common stock issued and outstanding		385,555,260
Warrants to purchase shares, description		the Company sold 17,500,000 shares of common stock for net proceeds of $77,409. With these issuances the company also issued warrants to purchase: (i) 17,500,000 shares at prices ranging from $0.05 to $0.10 per share and (ii) 14,500,000 shares at prices ranging from $0.10 to $0.20. The warrants expire at various times through September 21, 2022. None of the 17,500,000 shares were issued during the quarter ended September 30, 2020, and were recognized as stock payable. ●During the three months ended September 30, 2020, the Company issued 6,032,260 shares. Of these shares, 585,000 were issued for consulting services and 5,447,260 were converted from Preferred shares.	the Company sold for cash 6,337,500 shares of common stock and warrants to purchase: (i) 6,337,500 shares at prices ranging from $0.10 per share to $0.25 per share for net proceeds of $133,495. The warrants expire at various times through September 17, 2021. None of these shares were issued during the quarter ended September 30, 2019, with all 6,337,500 shares being recorded as stock payable. During the three months ended September 30, 2019, the Company issued 11,216,305 shares for cash. Of these shares, 7,991,662 were issued from stock payable and 3,224,643 were converted from Preferred shares.
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001		$ 0.001
Aggregate price (in Dollars)	$ (4,000,000)
Registration Statement, description	the Company shall have the discretion to deliver puts to GHS and GHS will be obligated to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice shall not exceed two hundred percent (200%) of the average daily trading dollar volume of the Company’s Common Stock during the ten (10) trading days preceding the put, so long as such dollar amount does not exceed $500,000. Pursuant to the Equity Financing Agreement, GHS and its affiliates will not be permitted to purchase and the Company may not put shares of the Company’s Common Stock to GHS that would result in GHS’s beneficial ownership, equaling more than 4.99% of the Company’s outstanding Common Stock. The price of each put share shall be equal to eighty percent (80%) of the Market Price (as defined in the Equity Financing Agreement). Puts may be delivered by the Company to GHS until the earlier of thirty-six (36) months after the effectiveness of the Registration Statement.
Fixed conversion price (in Dollars per share)		$ 0.0071
Class of warrants expire		82,882,681
Warrants are vested		84,882,681
Convertible promissory note [Member]
Stockholders' Deficit (Details) [Line Items]
Principal balance (in Dollars)	$ 35,000
Interest rate, percentage	10.00%
Fixed conversion price (in Dollars per share)	$ 0.0175
Deferred financing costs (in Dollars)	$ 35,000
GHS Investments, LLC [Member]
Stockholders' Deficit (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.001
Preferred Class B [Member]
Stockholders' Deficit (Details) [Line Items]
Preferred stock, shares authorized		5,000,000
Preferred stock, par value (in Dollars per share)		$ 0.001
Preferred stock, shares issued		610,000
Preferred stock, share outstanding		610,000
Series B Convertible Preferred Stock [Member]
Stockholders' Deficit (Details) [Line Items]
Preferred stock, shares authorized		5,000,000		5,000,000
Preferred stock, par value (in Dollars per share)		$ 0.001		$ 0.001
Preferred stock, shares issued		610,000		610,000
Preferred stock, share outstanding		610,000		610,000
Preferred stock shares									500,000
Preferred stock shares increased								5,000,000
Series B Convertible Preferred Stock [Member]
Stockholders' Deficit (Details) [Line Items]
Preferred stock, shares issued						210,000
Preferred stock, stated value per share (in Dollars per share)		$ 5

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity - $ / shares	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Minimum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range	$ 30	$ 30
Maximum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range	$ 2,020	$ 2,020
$0.05 - $1.00 [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Number of Warrants Outstanding (in Shares)	82,882,681
Weighted-Average Contractual Life Remaining in Years	1 year 98 days
Weighted- Average Exercise Price	$ 0.28
Number Exercisable (in Shares)	82,882,681
Weighted- Average Exercise Price	$ 0.28
$0.05 - $1.00 [Member] | Minimum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range	0.05
$0.05 - $1.00 [Member] | Maximum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range	$ 1
$0.20 - $1.00 [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Number of Warrants Outstanding (in Shares)		53,280,406
Weighted-Average Contractual Life Remaining in Years		1 year 43 days
Weighted- Average Exercise Price		$ 0.34
Number Exercisable (in Shares)		53,280,406
Weighted- Average Exercise Price		$ 0.34
$0.20 - $1.00 [Member] | Minimum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range		0.20
$0.20 - $1.00 [Member] | Maximum [Member]
Stockholders' Deficit (Details) - Schedule of share based compensation warrant activity [Line Items]
Exercise Prices Range		$ 1

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of warrant activity - shares	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Schedule of warrant activity [Abstract]
Outstanding - beginning of year	53,280,406	26,526,234
Issued	32,000,000	6,337,500
Exercised
Expired	(2,397,725)	(3,460,328)
Outstanding - end of year	82,882,681	29,403,406

Mandatory Redeemable Converti_3

Mandatory Redeemable Convertible Preferred Stock (Details) - USD ($)	Jan. 14, 2019	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Oct. 31, 2015
Mandatory Redeemable Convertible Preferred Stock (Details) [Line Items]
Preferred stock shares issued (in Shares)					200,000
Preferred shares convertible average market price rate		71.00%
Derivative inception value (in Dollars)		$ 43,945
Amortized utilizing effective interest discount amount (in Dollars)		$ 30,000
Conversion per share price (in Dollars per share)		$ 0.0071
Stock volatility rate minimum		225.00%
Stock volatility rate maximum		242.00%
Stock volatility discount rate (in Dollars)		$ 0.0015
Series C Convertible Preferred Stock [Member]
Mandatory Redeemable Convertible Preferred Stock (Details) [Line Items]
Preferred stock, authorized (in Shares)	1,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001
Preferred stock shares issued (in Shares)		148,000	117,200
Preferred stock shares outstanding (in Shares)		148,000	117,200
Series C mandatory redeemable convertible preferred stock [Member]
Mandatory Redeemable Convertible Preferred Stock (Details) [Line Items]
Dividend percent	10.00%
Description of conversion of stock		The Holder shall have the right at any time during the period beginning on the date which is six (6) months following the Issuance Date, to convert all or any part of the outstanding Series C Preferred Stock into fully paid and non-assessable shares of Common Stock at the Variable Conversion Price. The “Variable Conversion Price” shall mean 71% multiplied by the Market Price (representing a discount rate of 29%). “Market Price” means the average of the two (2) lowest Trading Prices (as defined here) for the Common Stock during the fifteen (15) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.
Fair value of convertible preferred stock (in Dollars)		$ 97,575		$ 90,751
Preferred shares, description		There were 72,600 Preferred C shares issued for net proceeds of $60,000 and 41,800 Preferred C shares converted to 5,447,260 Common shares for the three months ended September 30, 2020.
Series C mandatory redeemable convertible preferred stock [Member] | Minimum [Member]
Mandatory Redeemable Convertible Preferred Stock (Details) [Line Items]
Dividend percent	105.00%
Series C mandatory redeemable convertible preferred stock [Member] | Maximum [Member]
Mandatory Redeemable Convertible Preferred Stock (Details) [Line Items]
Dividend percent	130.00%

Mandatory Redeemable Converti_4

Mandatory Redeemable Convertible Preferred Stock (Details) - Schedule of derivative financial instruments, measured at fair value on a recurring basis	3 Months Ended
	Jun. 30, 2020USD ($)
Schedule of derivative financial instruments, measured at fair value on a recurring basis [Abstract]
Balance at Beginning	$ 43,831
Unamortized discount originated from derivative liabilities:	30,000
Financing costs recorded:	13,831
Derivative liability:	(43,831)
Change in fair market value of derivative liabilities:	(1,064)
Balance at Beginning	$ 42,767

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percentage	0.00%

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Nov. 17, 2020
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Subsequent event ,description	the Company has reviewed its operations subsequent to September 30, 2020 to the date these financial statements were issued. Between July 1, 2020 and November 17, 2020, the Company issued 21,117,205 shares of common stock. Of this amount, 6,172,205 shares were issued from 30,000 Preferred C shares that were converted and 14,945,000 shares were issued for cash and services.